AKTS

16.1501.52%
AC

Akos Czibere

Chief Medical Officer

Dr. Akos Czibere, M.D., Ph.D., is Chief Medical Officer of Aktis Oncology, Inc. from July 2024.He was Member of Scientific Advisory Board of Caribou Biosciences, Inc. from April 2024 until 2024. From April 2017 through July 2024 He has held vice president and therapeutic area head for hematology-oncology at Pfizer. With industry experience, he oversees the late-stage development and life cycle planning of the entire malignant hematology portfolio at Pfizer, including Elrexfio, Adcetris, Besponza, Myelotarg and Bosulif. Dr. Czibere held increasing levels of seniority at Merrimack Pharmaceuticals. He is the author peer reviewed publications and has been with Pfizer since 2017. Prior to his industry career, Akos was a postdoctoral research fellow at Beth Israel Deaconess Medical Center at Harvard Medical School in Dan Tenens lab investigating the role of long non-coding RNAs in myeloid differentiation. Akos is a hematologist and oncologist by training and received his MD and PhD from the University of Duesseldorf in Germany.

Positions